HCPCS for ZUSDURI™

J9282

Effective January 1st, 2026:

J9282: Mitomycin, intravesical instillation, 1 mg

Urogen Pharma is pleased to announce that ZUSDURI has been assigned a unique HCPCS J-Code by the Centers for Medicare & Medicaid Services (CMS): J9282. The HCPCS code is effective for dates of services on or after January 1, 2026.


Urogen Pharma would appreciate your partnership in updating systems and locations involved with the HCPCS and NDC information for J9282.


HCPCS Coding Information:

HCPCS Code

J9282

HCPCS Descriptor

Mitomycin, intravesical instillation, 1 mg

11-Digit NDC*

72493-0106-03

10-Digit NDC

72493-106-03

Package Description

One single-dose kit containing two 40 mg vials of mitomycin and one 60 mL vial of hydrogel

HCPCS Units per Package

80 mg

WAC Pricing

$21,500.00/per single dose kit

*11-digit NDC codes are used for claims processing and reimbursement.

 

CPT Administration Codes:

CPT Code

Code Descriptor

51720

Bladder instillation of an anticarcinogenic agent

Indications and Usage

ZUSDURI™ is indicated for the treatment of adult patients with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC).


IMPORTANT SAFETY INFORMATION

Contraindications

ZUSDURI is contraindicated in patients with perforation of the bladder or in patients with prior hypersensitivity reactions to mitomycin or any component of the product.


See Important Safety Information below.

How Supplied:

As per current label ZUSDURI is available in a kit (NDC 72493-106-03) containing the following:


  • Two 40 mg (each) single-dose vials of mitomycin for intravesical solution supplied as a sterile, lyophilized, grey to greyish-purple, cake or powder. (NDC 72493-104-40)


  • One single-dose vial of 60 mL sterile hydrogel supplied as a sterile, clear, colorless gel with or without bubbles at room temperature or clear, colorless liquid at 2°C to 8°C (36°F to 46°F), to be used as a vehicle for reconstitution. (NDC 72493-105-60)


Reconstitution:

ZUSDURI must be reconstituted by a healthcare professional prior to use. See the Instructions for Pharmacy for a full description of the process to reconstitute ZUSDURI.

The dose of ZUSDURI to be instilled is 75 mg (56 mL) administered. Both 40 mg vials of ZUSDURI must be reconstituted using the sterile hydrogel to achieve the recommended dose of ZUSDURI. 


A single vial of mitomycin (40 mg) cannot be used to successfully reconstitute ZUSDURI to the required concentration of 75 mg (56 mL).

 
 

For assistance, call 1-833-UROGEN1 (1-833-876-4361) or visit UROGENSUPPORT.com

 

ZUSDURI™ (mitomycin) for Intravesical Use

Important Safety Information


Indications and Usage

ZUSDURI™ is indicated for the treatment of adult patients with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC).



IMPORTANT SAFETY INFORMATION


Contraindications

ZUSDURI is contraindicated in patients with perforation of the bladder or in patients with prior hypersensitivity reactions to mitomycin or any component of the product.

 

Warnings and Precautions

Risks in Patients with Perforated Bladder

ZUSDURI may lead to systemic exposure to mitomycin and severe adverse reactions if administered to patients with a perforated bladder or to those in whom the integrity of the bladder mucosa has been compromised. Evaluate the bladder before the intravesical instillation of ZUSDURI and do not administer to patients with a perforated bladder or mucosal compromise until bladder integrity has been restored.


Embryo-Fetal Toxicity

Based on findings in animals and mechanism of action, ZUSDURI can cause fetal harm when administered to a pregnant woman. In animal reproduction studies, administration of mitomycin resulted in teratogenicity. Advise females of reproductive potential to use effective contraception during treatment with ZUSDURI and for 6 months following the last dose. Advise male patients with female partners of reproductive potential to use effective contraception during treatment with ZUSDURI and for 3 months following the last dose.

 

Adverse Reactions

Common Adverse Reactions

The most common (≥10%) adverse reactions, including laboratory abnormalities, that occurred in patients treated with ZUSDURI were increased creatinine, increased potassium, dysuria, decreased hemoglobin, increased aspartate aminotransferase, increased alanine aminotransferase, increased eosinophils, decreased lymphocytes, urinary tract infection, decreased neutrophils, and hematuria.


Additional Adverse Reactions Information

Clinically relevant adverse reactions occurring in <10% of patients who received ZUSDURI included increased urinary frequency, fatigue, urinary incontinence, urinary retention, urethral stenosis, genital pain, urinary urgency, genital edema, genital pruritus, genital rash, urethritis, acute kidney injury, balanoposthitis, and nocturia.


Use in Specific Populations

Lactation

Because of the potential for serious adverse reactions in a breastfed child, advise women not to breastfeed during treatment with ZUSDURI and for 1 week following the last dose.


Preparation and Administration Information

ZUSDURI is to be administered by intravesical instillation only. Do not administer ZUSDURI by pyelocalyceal instillation or by any other route.


ZUSDURI must be prepared and administered by a healthcare provider. To ensure proper dosing, it is important to follow the preparation instructions found in the ZUSDURI Instructions for Pharmacy and administration instructions found in the ZUSDURI


Instructions for Administration.

ZUSDURI may discolor urine to a violet to blue color following the instillation procedure. Advise patients for at least 24 hours post-instillation to avoid urine contact with skin, to void urine sitting on a toilet, and to flush the toilet several times after use. Advise patients to wash hands, perineum or glans with soap and water after each instillation procedure. 

 

ZUSDURI is a hazardous drug. Follow applicable special handling and disposal procedures.


Please see accompanying Full Prescribing Information, Instructions for Pharmacy and Instructions for Administration.

 

ZUSDURI™ and UroGen Support™ are trademarks and UroGen® and RTGel® are registered trademarks of UroGen Pharma, Ltd.

All other trademarks are the property of their respective owners.

© 2025 UroGen Pharma, Inc. All rights reserved. US-ZUS-00196